How long gynaecomastia lasts depends on its cause, the age of onset, and whether treatment is sought. Gynaecomastia — the benign enlargement of glandular breast tissue in males — is a common condition that ranges from a temporary hormonal fluctuation in newborns or adolescents to a persistent, fibrotic change in adult men. Pubertal cases often resolve spontaneously within six months to two years, whilst adult-onset gynaecomastia can be more enduring. Understanding the likely timeline, the factors that influence duration, and when to seek medical advice is essential for anyone affected by this condition.

How Long Does Gynaecomastia Typically Last?

Pubertal gynaecomastia typically resolves within six months to two years; neonatal cases clear within weeks, whilst adult-onset gynaecomastia is often more persistent and closely tied to the underlying cause.

Gynaecomastia — the benign enlargement of glandular breast tissue in males — is a condition that varies considerably in duration depending on its underlying cause, the age at which it develops, and whether any treatment is pursued. In many cases, particularly those arising during puberty, the condition resolves spontaneously within six months to two years without any medical intervention.

For neonatal gynaecomastia, which occurs in newborn boys due to the transfer of maternal oestrogens, resolution typically happens within a few weeks, though in some cases it may take a little longer. Pubertal gynaecomastia, the most common form, generally peaks between the ages of 13 and 14 and tends to resolve by the late teenage years in the majority of cases. However, in a small minority of adolescents — estimated at around 10–20% — the condition may persist beyond one to two years if left unaddressed (NHS; NICE CKS: Gynaecomastia).

In adult men, particularly those over 50, gynaecomastia may be more persistent. Age-related hormonal shifts, including declining testosterone and relatively higher oestrogen levels, can sustain breast tissue growth over a longer period. When gynaecomastia is linked to an underlying medical condition or medication, duration is closely tied to how effectively the root cause is managed. Understanding the likely timeline is important for setting realistic expectations and deciding when to seek professional advice.

Stages of Gynaecomastia and What to Expect Over Time

Gynaecomastia progresses from an early florid stage (active tissue proliferation, often with tenderness) to a fibrous chronic stage after approximately 12 months, at which point spontaneous resolution and medical treatment become significantly less likely.

Gynaecomastia progresses through recognised stages, and understanding these can help clinicians anticipate how the condition may evolve. It is often classified clinically using the Simon or Rohrich grading systems — tools used by clinicians (not for self-assessment) that range from minor subareolar tissue enlargement to significant breast development with excess skin.

In the early or florid stage (typically the first four to six months, though timeframes are approximate and vary between individuals), there is active proliferation of ductal tissue and surrounding stroma. This phase is often associated with tenderness or sensitivity around the nipple area. During this stage, the tissue is more responsive to hormonal changes and, in some cases, to medical treatment.

As the condition progresses into the intermediate stage, fibrous tissue begins to replace the more active glandular tissue. Tenderness may reduce, but the breast enlargement becomes more established. After approximately 12 months, gynaecomastia is generally considered to have entered the fibrous or chronic stage, in which dense fibrosis predominates. At this point:

• Spontaneous resolution becomes significantly less likely

• Medical treatments such as anti-oestrogens are generally less effective, as supported by clinical evidence

• Surgical intervention may be the most reliable option for those seeking resolution

Recognising which stage a patient is in helps guide clinical decision-making. Early presentation to a GP is therefore advisable, as intervention during the florid stage offers the best chance of non-surgical resolution.

Factors That Affect How Long Gynaecomastia Persists

Duration is influenced by age at onset, underlying medical conditions, causative medications, obesity, and how long the condition existed before diagnosis — addressing modifiable factors can shorten its course.

Several factors influence whether gynaecomastia resolves quickly, persists for years, or becomes a permanent feature. Identifying these factors is central to understanding an individual's prognosis.

Age at onset plays a significant role. Pubertal gynaecomastia in otherwise healthy adolescents has a favourable natural history, whereas gynaecomastia developing in middle-aged or older men tends to be more persistent due to sustained hormonal imbalance.

Underlying causes are equally important. Gynaecomastia secondary to identifiable conditions — such as hypogonadism, hyperthyroidism, liver cirrhosis, renal failure, or oestrogen- or hCG-secreting tumours (including testicular tumours) — is unlikely to resolve until the primary condition is adequately treated.

Medication-induced gynaecomastia is a common and important cause. Drugs associated with gynaecomastia include, but are not limited to:

• Anti-androgens (e.g., bicalutamide, cyproterone acetate) and androgen deprivation therapy

• 5-alpha-reductase inhibitors (e.g., finasteride, dutasteride)

• Spironolactone

• Anabolic steroids and exogenous oestrogens

• Anti-retrovirals (e.g., efavirenz)

• Digoxin and ketoconazole

• Certain antipsychotics and other psychotropic medicines

• Cimetidine (now less commonly used)

Medication-induced gynaecomastia may persist for some months after the offending drug is discontinued, though it often improves once the causative agent is removed. Patients should not stop prescribed medicines without first discussing this with their GP or specialist. If you suspect a medicine is causing gynaecomastia, this can be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

Other contributing factors include:

• Body weight: Obesity increases peripheral conversion of androgens to oestrogens via aromatase activity in adipose tissue, prolonging hormonal imbalance

• Duration before diagnosis: Longer-standing gynaecomastia is more likely to have undergone fibrosis, reducing the chance of spontaneous resolution

• Alcohol and recreational drug use: Cannabis has been associated with gynaecomastia in some reports, though the evidence is inconsistent and does not establish causation

• Anabolic steroid use: A well-recognised cause that can lead to persistent breast tissue changes even after cessation

Addressing modifiable risk factors — such as reviewing medications with a clinician, managing weight, and treating underlying conditions — can meaningfully shorten the duration of gynaecomastia (NICE CKS: Gynaecomastia).

When to See a GP About Breast Tissue Changes

See a GP promptly if a breast lump is hard, irregular, or fixed, or if there is nipple discharge, skin changes, or unilateral rapid swelling, as these features require urgent assessment to exclude male breast cancer.

Whilst gynaecomastia is most often benign, it is important not to dismiss breast tissue changes in males without appropriate evaluation. The NHS recommends that any new or unexplained breast lump in a man should be assessed by a GP, as a small number of cases may represent male breast cancer, which accounts for approximately 1% of all breast cancer diagnoses in the UK.

You should contact your GP promptly if you notice any of the following:

• A hard, irregular, or fixed lump in the breast, particularly if not centred beneath the nipple

• Unilateral (one-sided) breast swelling that is rapidly enlarging

• Nipple discharge, especially if bloodstained

• Skin changes over the breast, such as dimpling, puckering, or ulceration

• Nipple inversion that has developed recently

• Axillary (armpit) lymph node enlargement

• Breast changes accompanied by unexplained weight loss, fatigue, or systemic symptoms

Where any of these features are present, your GP may make an urgent suspected cancer referral to a breast clinic under the two-week-wait pathway, in line with NICE guideline NG12 (Suspected cancer: recognition and referral).

For adolescents, a GP visit is advisable if gynaecomastia has not shown signs of improvement after two years, is causing significant psychological distress, or is associated with other signs of hormonal abnormality. Adults who develop gynaecomastia without an obvious cause should also seek evaluation, as investigations may be needed to exclude secondary causes.

GPs may arrange blood tests including LH, FSH, testosterone, oestradiol, prolactin, hCG, sex hormone-binding globulin (SHBG), and liver, thyroid, and renal function tests. Where a testicular or other tumour is suspected, testicular examination and ultrasound may also be arranged. Depending on findings, referral to an endocrinologist or breast surgeon may follow. Early assessment ensures that any treatable underlying cause is identified and that appropriate reassurance or onward referral is provided in a timely manner.

Treatment Options Available on the NHS

NHS treatment ranges from watchful waiting in pubertal cases to off-label medical therapy (e.g., tamoxifen) in the early florid stage, and subcutaneous mastectomy for chronic fibrotic gynaecomastia, subject to ICB commissioning criteria.

Treatment for gynaecomastia on the NHS is guided by the underlying cause, the stage of the condition, and the degree of physical or psychological impact on the individual. NICE does not currently have a dedicated guideline specifically for gynaecomastia, but management broadly follows established endocrinological and surgical principles, as outlined in NICE CKS: Gynaecomastia.

Watchful waiting is the first-line approach for pubertal gynaecomastia, given its high rate of spontaneous resolution. Regular review and reassurance are provided, with intervention considered only if the condition persists or causes significant distress.

Medical treatment may be considered in the early florid stage, under specialist supervision. All medicines used for gynaecomastia in the UK are prescribed off-label, and decisions are made on an individual basis by an endocrinologist or specialist. Options include:

• Tamoxifen (an oestrogen receptor antagonist / SERM): Has demonstrated some efficacy in reducing breast tissue volume and tenderness in early-stage gynaecomastia in clinical studies. As with all SERMs, there is a potential risk of venous thromboembolism (VTE); patients should be counselled accordingly.

• Raloxifene: Another selective oestrogen receptor modulator (SERM) sometimes used in specialist settings, also off-label.

• Aromatase inhibitors (e.g., anastrozole): The evidence base for their use in gynaecomastia is limited, and they are not routinely recommended, particularly in pubertal gynaecomastia. They may occasionally be considered in specific adult cases under specialist guidance.

Patients should not attempt to obtain or use these medicines without a prescription and specialist oversight. Suspected adverse effects of any medicine should be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

Experiencing these side effects? Our pharmacists can help you navigate them →

Surgical treatment — most commonly subcutaneous mastectomy (gland excision), with or without liposuction-assisted techniques — is considered for chronic, fibrotic gynaecomastia that has not responded to conservative measures. NHS funding for surgery is subject to local Integrated Care Board (ICB) commissioning policies and NHS England Evidence-Based Interventions (EBI) guidance, and is generally reserved for cases causing significant functional impairment or psychological harm. Patients seeking surgery primarily for cosmetic reasons may be directed towards private providers.

Does Gynaecomastia Go Away Without Treatment?

Approximately 75–90% of pubertal gynaecomastia cases resolve spontaneously within one to three years, but once fibrosis develops after 12 months, self-resolution is unlikely and surgery is usually required.

For many men and adolescents, gynaecomastia does resolve without any formal treatment, particularly when it arises during puberty or is linked to a transient hormonal fluctuation. Studies suggest that approximately 75–90% of pubertal cases resolve spontaneously within one to three years (NICE CKS: Gynaecomastia; BMJ Best Practice). This natural resolution occurs as the hormonal imbalance between oestrogen and testosterone corrects itself during the course of normal development.

However, the likelihood of spontaneous resolution diminishes significantly with time. Once gynaecomastia has been present for more than 12 months, the glandular tissue tends to undergo fibrosis — a process in which active breast tissue is replaced by scar-like fibrous tissue. Fibrotic gynaecomastia is unlikely to resolve on its own and is generally unresponsive to medical therapy, making surgical intervention the most effective option for those who wish to address it.

In adult-onset gynaecomastia, spontaneous resolution is less predictable and depends heavily on whether the underlying cause is identified and corrected. For example:

• Gynaecomastia caused by a medication may improve within three to six months of stopping the drug, though this is variable and depends on the duration of use and the stage of the condition — always discuss stopping any prescribed medicine with your GP or specialist first

• Cases linked to weight gain may partially improve with sustained weight loss

• Gynaecomastia secondary to hypogonadism may respond to testosterone replacement therapy (TRT) under specialist supervision; however, TRT can initially worsen gynaecomastia through aromatisation of testosterone to oestrogen, and management should be specialist-led

It is worth emphasising that pseudogynecomastia — breast enlargement due to excess fatty tissue rather than true glandular proliferation — is not gynaecomastia in the clinical sense and may improve with weight management alone. A GP can help distinguish between the two. Overall, early assessment remains the best approach to understanding whether watchful waiting is appropriate or whether intervention is warranted (NHS: Gynaecomastia; NICE CKS: Gynaecomastia).

Frequently Asked Questions